RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims & Hers Health may benefit from a potential expansion into peptides following an FDA review process initiated by HHS Secretary Robert F. Kennedy Jr. The company has already acquired a peptide facility and is positioning itself for new revenue streams as it shifts from compounded GLP-1 drugs to branded alternatives. The FDA's Pharmacy Compounding Advisory Committee is set to meet in July 2026 to review peptides for inclusion on the 503A bulk list.
Tickers: $HIMS
Topics: compounding drugs FDA Hims & Hers Health peptides telehealth